USPTO serial 98094108
GLPG
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BERLIN, JUSTIN E
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLPG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
ALEXANDRA MACKAY STITES & HARBISON PLLC401 COMMERCE STREETSUITE 800NASHVILLE, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical substances and preparations for human use, namely, for the treatment of inflammatory diseases, autoinflammation diseases, autoimmune diseases, proliferative diseases, cancer, skin diseases, cardiovascular diseases, anti-infectives, hepatitis B virus, osteoarthritis, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma; biopharmaceutical substances and preparations for human use, namely, for the treatment of inflammatory diseases, autoinflammation diseases, autoimmune diseases, proliferative diseases, cancer, skin diseases, cardiovascular diseases, anti-infectives, hepatitis B virus, osteoarthritis, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma | ACTIVE | — |
| 042 | medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, chimeric antigen receptor T-cell therapy, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields and gathering of data to populate those databases via collection of medical, pharmaceutical, biopharmaceutical research and clinical trial data; gene bank services for research purposes | ACTIVE | — |
| 044 | medical services; medical and pharmaceutical advisory and consultancy services; gene bank services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Galapagos NV
- Other trademarks owned by Galapagos NV
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GLPG
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 12, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 1, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 28, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 6, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 13, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 26, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 24, 2023 | NWAP | NEW APPLICATION ENTERED | — |